Gilead Hepatitis C Drug Wins EU Panel Vote Early
Gilead Sciences’ (GILD) hepatitis C drug sofosbuvir won a European advisory panel vote earlier than Wall Street expected Friday, sending the stock up more than 4% to an all-time high on the stock market today. The EU’s Committee for Medicinal Products for Human Use (CHMP) recommended approving sofosbuvir, now branded Sovaldi, following an accelerated review procedure after the drug performed very well in clinical trials. The European Commission